A rigorous new systematic review and meta-analysis of 20 high-quality trials (3,459 patients) confirms that low-dose, short-course systemic corticosteroids significantly reduce short-term mortality in both severe pneumonia (RR 0.73, 95% CI 0.57–0.93, moderate certainty) and ARDS (RR 0.77, 95% CI 0.61–0.99, moderate certainty), while cutting the risk of secondary shock in severe pneumonia nearly in half (RR 0.49, low certainty).

Crucially, these benefits come with reassuring evidence of little to no increase in hospital-acquired infections, secondary pneumonia, or catheter-related bloodstream infections (RRs hovering around 0.9–1.0, mostly moderate-to-low certainty).

The findings strengthen the case for routine adjunctive steroids in these life-threatening conditions, showing that the mortality advantage is real and the long-feared infection penalty appears minimal or nonexistent when dosing is kept low and duration short.

Read More